Phosphorylation of FOXO3a on Ser-7 by p38 Promotes Its Nuclear Localization in Response to Doxorubicin

被引:109
作者
Ho, Ka-Kei [1 ]
McGuire, Victoria A. [2 ]
Koo, Chuay-Yeng [1 ]
Muir, Kyle W. [1 ]
de Olano, Natalia [1 ]
Maifoshie, Evie [1 ]
Kelly, Douglas J. [1 ,3 ]
McGovern, Ursula B. [1 ]
Monteiro, Lara J. [1 ]
Gomes, Ana R. [1 ]
Nebreda, Angel R. [4 ,5 ]
Campbell, David G. [2 ]
Arthur, J. Simon C. [2 ]
Lam, Eric W. -F. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London W12 0NN, England
[2] Univ Dundee, Med Res Council Prot Phosphorylat Unit, Sch Life Sci, Dundee DD1 5EH, Scotland
[3] Univ London Imperial Coll Sci Technol & Med, Dept Phys, London SW7 2AZ, England
[4] Inst Catalana Recerca & Estudis Avancats, Barcelona 08028, Spain
[5] Inst Res Biomed IRB Barcelona, Barcelona 08028, Spain
基金
英国工程与自然科学研究理事会;
关键词
TRANSCRIPTION FACTOR FOXO3A; BREAST-CANCER CELLS; MAP KINASE; INDUCED ACTIVATION; INDUCED APOPTOSIS; FOXM1; EXPRESSION; GEFITINIB IRESSA; GENE-EXPRESSION; TARGET; STRESS;
D O I
10.1074/jbc.M111.284224
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
FOXO3a is a forkhead transcription factor that regulates a multitude of important cellular processes, including proliferation, apoptosis, differentiation, and metabolism. Doxorubicin treatment of MCF-7 breast carcinoma cells results in FOXO3a nuclear relocation and the induction of the stress-activated kinase p38 MAPK. Here, we studied the potential regulation of FOXO3a by p38 in response to doxorubicin. Co-immunoprecipitation studies in MCF-7 cells demonstrated a direct interaction between p38 and FOXO3a. We also showed that p38 can bind and phosphorylate a recombinant FOXO3a directly in vitro. HPLC-coupled phosphopeptide mapping and mass spectrometric analyses identified serine 7 as a major site for p38 phosphorylation. Using a phosphorylated Ser-7 FOXO3a antibody, we demonstrated that FOXO3a is phosphorylated on Ser-7 in response to doxorubicin. Immunofluorescence staining studies showed that upon doxorubicin treatment, the wild-type FOXO3a relocalized to the nucleus, whereas the phosphorylation-defective FOXO3a (Ala-7) mutant remained largely in the cytoplasm. Treatment with SB202190 also inhibits the doxorubicin-induced FOXO3a Ser-7 phosphorylation and nuclear accumulation in MCF-7 cells. In addition, doxorubicin caused the nuclear translocation of FOXO3a in wild-type but not p38-depleted mouse fibroblasts. Together, our results suggest that p38 phosphorylation of FOXO3a on Ser-7 is essential for its nuclear relocalization in response to doxorubicin.
引用
收藏
页码:1545 / 1555
页数:11
相关论文
共 64 条
  • [41] ATM and p53 Regulate FOXM1 Expression via E2F in Breast Cancer Epirubicin Treatment and Resistance
    Millour, Julie
    de Olano, Natalia
    Horimoto, Yoshiya
    Monteiro, Lara J.
    Langer, Julia K.
    Aligue, Rosa
    Hajji, Nabil
    Lam, Eric W. -F.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (06) : 1046 - 1058
  • [42] The emerging roles of forkhead box (Fox) proteins in cancer
    Myatt, Stephen S.
    Lam, Eric W. -F.
    [J]. NATURE REVIEWS CANCER, 2007, 7 (11) : 847 - 859
  • [43] Sense and Sensitivity: FOXO and ROS in Cancer Development and Treatment
    Myatt, Stephen S.
    Brosens, Jan J.
    Lam, Eric W. -F.
    [J]. ANTIOXIDANTS & REDOX SIGNALING, 2011, 14 (04) : 675 - 687
  • [44] Nagai H, 2007, J BIOCHEM MOL BIOL, V40, P1
  • [45] Caenorhabditis elegans Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor
    Paradis, S
    Ruvkun, G
    [J]. GENES & DEVELOPMENT, 1998, 12 (16) : 2488 - 2498
  • [46] Raingeaud J, 1996, MOL CELL BIOL, V16, P1247
  • [47] Sanchez-Prieto R, 2000, CANCER RES, V60, P2464
  • [48] Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors
    Savarese, DMF
    Hsieh, CC
    Stewart, FM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (08) : 2981 - 2995
  • [49] She QB, 2001, CANCER RES, V61, P1604
  • [50] Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin
    Shiota, Masaki
    Yokomizo, Akira
    Kashiwagi, Eiji
    Tada, Yasuhiro
    Inokuchi, Junichi
    Tatsugami, Katsunori
    Kuroiwa, Kentaro
    Uchiumi, Takeshi
    Seki, Narihito
    Naito, Seiji
    [J]. CANCER SCIENCE, 2010, 101 (05) : 1177 - 1185